![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Treatment with KTX-0200 led to sustained weight loss of 14% in chronic diet-induced obesity rodent models known to be predictive of clinical efficacy across anti-obesity drug mechanisms.
Lead Product(s): KTX-0200
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2020
Details:
Company receives FDA guidance for pivotal trial design in follicular lymphoma to support accelerated and full approval.
Lead Product(s): Apilimod mesylate,Rituximab,Atezolizumab
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2020